Advice

in the absence of a submission from the holder of the marketing authorisation:

raltegravir (IsentressĀ®) is not recommended for use within NHSScotland.

Indication under review: in combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download full details135KB (PDF)

Download

Medicine details

Medicine name:
raltegravir (Isentress)
SMC ID:
SMC2101
Indication:
in combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.
Pharmaceutical company
MSD
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published:
09 July 2018